GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Shyndec Pharmaceutical Co Ltd (SHSE:600420) » Definitions » Beneish M-Score

Shanghai Shyndec Pharmaceutical Co (SHSE:600420) Beneish M-Score : -2.99 (As of Apr. 23, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Shanghai Shyndec Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.99 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shanghai Shyndec Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

SHSE:600420' s Beneish M-Score Range Over the Past 10 Years
Min: -3.58   Med: -2.66   Max: -0.01
Current: -2.99

During the past 13 years, the highest Beneish M-Score of Shanghai Shyndec Pharmaceutical Co was -0.01. The lowest was -3.58. And the median was -2.66.


Shanghai Shyndec Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Shanghai Shyndec Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Shyndec Pharmaceutical Co Beneish M-Score Chart

Shanghai Shyndec Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.29 -2.59 -2.97 -2.54 -2.99

Shanghai Shyndec Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.54 -2.75 -2.87 -2.91 -2.99

Competitive Comparison of Shanghai Shyndec Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Shyndec Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Shyndec Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Shyndec Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shanghai Shyndec Pharmaceutical Co's Beneish M-Score falls into.


;
;

Shanghai Shyndec Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shanghai Shyndec Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7477+0.528 * 0.9766+0.404 * 0.9389+0.892 * 0.9062+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5655+4.679 * -0.058748-0.327 * 0.8747
=-2.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was ¥1,447 Mil.
Revenue was 2344.203 + 2633.228 + 2836.686 + 3123.408 = ¥10,938 Mil.
Gross Profit was 881.765 + 1048.485 + 1088.52 + 1273.54 = ¥4,292 Mil.
Total Current Assets was ¥11,684 Mil.
Total Assets was ¥19,956 Mil.
Property, Plant and Equipment(Net PPE) was ¥5,550 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,028 Mil.
Total Current Liabilities was ¥4,344 Mil.
Long-Term Debt & Capital Lease Obligation was ¥48 Mil.
Net Income was 129.096 + 236.049 + 387.22 + 331.257 = ¥1,084 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 229.521 + 209.453 + 1105.602 + 711.405 = ¥2,256 Mil.
Total Receivables was ¥2,135 Mil.
Revenue was 2908.049 + 2717.355 + 3027.357 + 3417.169 = ¥12,070 Mil.
Gross Profit was 1063.775 + 1037.716 + 1140.163 + 1384.263 = ¥4,626 Mil.
Total Current Assets was ¥10,657 Mil.
Total Assets was ¥19,352 Mil.
Property, Plant and Equipment(Net PPE) was ¥5,885 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥2,006 Mil.
Total Current Liabilities was ¥3,780 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,089 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1446.546 / 10937.525) / (2134.87 / 12069.93)
=0.132255 / 0.176875
=0.7477

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4625.917 / 12069.93) / (4292.31 / 10937.525)
=0.38326 / 0.392439
=0.9766

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11684.104 + 5550.447) / 19955.597) / (1 - (10656.992 + 5884.658) / 19352.282)
=0.136355 / 0.145235
=0.9389

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=10937.525 / 12069.93
=0.9062

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 5884.658)) / (0 / (0 + 5550.447))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1028.138 / 10937.525) / (2006.256 / 12069.93)
=0.094001 / 0.166219
=0.5655

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((47.937 + 4343.611) / 19955.597) / ((1088.923 + 3779.675) / 19352.282)
=0.220066 / 0.251577
=0.8747

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1083.622 - 0 - 2255.981) / 19955.597
=-0.058748

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shanghai Shyndec Pharmaceutical Co has a M-score of -2.99 suggests that the company is unlikely to be a manipulator.


Shanghai Shyndec Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Shanghai Shyndec Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Shyndec Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.1320 Beijinxi Road, Shanghai, CHN, 200040
Shanghai Shyndec Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical preparations, biological pharmaceuticals, chemical raw materials, and Chinese medicine formulations in China and internationally. It provides biological and chemical raw material medicines, microbial fermentation products and tablets, capsules, granules, injections, suspensions, and suppositories, as well as ointments, including product formulations.
Executives
Li Hao senior management
Ni Feng Director
Li Xian Lin senior management
Hao Chao Feng senior management
Lian Wan Yong Director
Han Yan Lin Director
Yang Wen Ming Supervisors
Feng Ming Director

Shanghai Shyndec Pharmaceutical Co Headlines

No Headlines